Insights into gastroesophageal reflux disease-associated dyspeptic symptoms

Clinical Gastroenterology and Hepatology

Volumn 9, Issue 10, 2011, Pages 824-833

  Gerson, Lauren B ^a   Kahrilas, Peter J ^b   Fass, Ronnie ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

Dyspeptic Symptoms; Gastroesophageal Reflux Disease (GERD); Proton Pump Inhibitors; Quality of Life

Indexed keywords

PROTON PUMP INHIBITOR;

BLOATING; DISEASE ASSOCIATION; DYSPEPSIA; EPIGASTRIC PAIN; EVALUATION; GASTROESOPHAGEAL REFLUX; HUMAN; NAUSEA AND VOMITING; PATHOPHYSIOLOGY; PREVALENCE; QUALITY OF LIFE; REFLUX ESOPHAGITIS; REVIEW; RISK ASSESSMENT; STRUCTURED QUESTIONNAIRE; SYMPTOM; SYSTEMATIC REVIEW;

DYSPEPSIA; GASTROESOPHAGEAL REFLUX; HUMANS; PREVALENCE;

EID: 79961209469     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2011.05.015     Document Type: Review

References (59)

1. Locke G.R., Talley N.J., Fett S.L., et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997, 112:1448-1456.
2. Vakil N., van Zanten S.V., Kahrilas P., et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006, 101:1900-1920. quiz 1943.
3. Bardhan K.D., Stanghellini V., Armstrong D., et al. Evaluation of GERD symptoms during therapy: part I-development of the new GERD questionnaire ReQuest. Digestion 2004, 69:229-237.
4. Damiano A., Handley K., Adler E., et al. Measuring symptom distress and health-related quality of life in clinical trials of gastroesophageal reflux disease treatment: further validation of the Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS). Dig Dis Sci 2002, 47:1530-1537.
5. Kahrilas P.J., Miner P., Johanson J., et al. Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease. Dig Dis Sci 2005, 50:2009-2018.
6. Dent J., Brun J., Fendrick A.M., et al. An evidence-based appraisal of reflux disease management: the Genval Workshop Report. Gut 1999, 44(Suppl 2):S1-S16.
7. Tack J., Talley N.J., Camilleri M., et al. Functional gastroduodenal disorders. Gastroenterology 2006, 130:1466-1479.
8. Camilleri M., Dubois D., Coulie B., et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol 2005, 3:543-552.
9. Papatheodoridis G.V., Karamanolis D.G. Prevalence and impact of upper and lower gastrointestinal symptoms in the Greek urban general population. Scand J Gastroenterol 2005, 40:412-421.
10. Haque M., Wyeth J.W., Stace N.H., et al. Prevalence, severity and associated features of gastro-oesophageal reflux and dyspepsia: a population-based study. N Z Med J 2000, 113:178-181.
11. Chiocca J.C., Olmos J.A., Salis G.B., et al. Prevalence, clinical spectrum and atypical symptoms of gastro-oesophageal reflux in Argentina: a nationwide population-based study. Aliment Pharmacol Ther 2005, 22:331-342.
12. Rey E., Elola-Olaso C.M., Rodríguez-Artalejo F., et al. Prevalence of atypical symptoms and their association with typical symptoms of gastroesophageal reflux in Spain. Eur J Gastroenterol Hepatol 2006, 18:969-975.
13. Choung R.S., Locke G.R., Schleck C.D., et al. Do distinct dyspepsia subgroups exist in the community?. A population-based study. Am J Gastroenterol 2007, 102:1983-1989.
14. Kitapçioǧlu G., Mandiracioǧlu A., Caymaz-Bor C., et al. Overlap of symptoms of dyspepsia and gastroesophageal reflux in the community. Turk J Gastroenterol 2007, 18:14-19.
15. Wong W.M., Lai K.C., Lam K.F., et al. Prevalence, clinical spectrum and health care utilization of gastro-oesophageal reflux disease in a Chinese population: a population-based study. Aliment Pharmacol Ther 2003, 18:595-604.
16. Shah S.S., Bhatia S.J., Mistry F.P. Epidemiology of dyspepsia in the general population in Mumbai. Indian J Gastroenterol 2001, 20:103-106.
17. Li Y.M., Du J., Zhang H., et al. Epidemiological investigation in outpatients with symptomatic gastroesophageal reflux from the Department of Medicine in Zhejiang Province, east China. J Gastroenterol Hepatol 2008, 23:283-289.
18. Lee S.Y., Lee K.J., Kim S.J., et al. Prevalence and risk factors for overlaps between gastroesophageal reflux disease, dyspepsia, and irritable bowel syndrome: a population-based study. Digestion 2009, 79:196-201.
19. Kaji M., Fujiwara Y., Shiba M., et al. Prevalence of overlaps between GERD, FD and IBS and impact on health-related quality of life. J Gastroenterol Hepatol 2010, 25:1151-1156.
20. Noh Y.W., Jung H.K., Kim S.E., et al. Overlap of erosive and non-erosive reflux diseases with functional gastrointestinal disorders according to Rome III criteria. Neurogastroenterol Motil 2010, 16:148-156.
21. Kennedy T., Jones R. The prevalence of gastro-oesophageal reflux symptoms in a UK population and the consultation behaviour of patients with these symptoms. Aliment Pharmacol Ther 2000, 14:1589-1594.
22. Carlsson R., Dent J., Watts R., et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole-International GORD Study Group. Eur J Gastroenterol Hepatol 1998, 10:119-124.
23. Drossman D.A. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006, 130:1377-1390.
24. Wallander M.A., Johansson S., Ruigómez A., et al. Dyspepsia in general practice: incidence, risk factors, comorbidity and mortality. Fam Pract 2007, 24:403-411.
25. Hansen J.M., Wildner-Christensen M., Schaffalitzky de Muckadell O.B. Gastroesophageal reflux symptoms in a Danish population: a prospective follow-up analysis of symptoms, quality of life, and health-care use. Am J Gastroenterol 2009, 104:2394-2403.
26. El-Serag H.B. Epidemiology of non-erosive reflux disease. Digestion 2008, 78(Suppl 1):6-10.
27. Savarino E., Pohl D., Zentilin P., et al. Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. Gut 2009, 58:1185-1191.
28. Fass R., Naliboff B., Higa L., et al. Differential effect of long-term esophageal acid exposure on mechanosensitivity and chemosensitivity in humans. Gastroenterology 1998, 115:1363-1373.
29. Rao S.S., Gregersen H., Hayek B., et al. Unexplained chest pain: the hypersensitive, hyperreactive, and poorly compliant esophagus. Ann Intern Med 1996, 124:950-958.
30. Wu J.C., Cheung C.M., Wong V.W., et al. Distinct clinical characteristics between patients with nonerosive reflux disease and those with reflux esophagitis. Clin Gastroenterol Hepatol 2007, 5:690-695.
31. Tack J., Caenepeel P., Fischler B., et al. Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia. Gastroenterology 2001, 121:526-535.
32. Buckles D.C., Sarosiek I., McMillin C., et al. Delayed gastric emptying in gastroesophageal reflux disease: reassessment with new methods and symptomatic correlations. Am J Med Sci 2004, 327:1-4.
33. Emerenziani S., Sifrim D. New developments in detection of gastroesophageal reflux. Curr Opin Gastroenterol 2005, 21:450-453.
34. McCallum R.W., Chen J.D., Lin Z., et al. Gastric pacing improves emptying and symptoms in patients with gastroparesis. Gastroenterology 1998, 114:456-461.
35. Revicki D.A., Wood M., Maton P.N., et al. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998, 104:252-258.
36. Gerson L.B., Ullah N., Hastie T., et al. Patient-derived health state utilities for gastroesophageal reflux disease. Am J Gastroenterol 2005, 100:524-533.
37. Wahlqvist P., Karlsson M., Johnson D., et al. Relationship between symptom load of gastro-oesophageal reflux disease and health-related quality of life, work productivity, resource utilization and concomitant diseases: survey of a US cohort. Aliment Pharmacol Ther 2008, 27:960-970.
38. Brook R.A., Wahlqvist P., Kleinman N.L., et al. Cost of gastro-oesophageal reflux disease to the employer: a perspective from the United States. Aliment Pharmacol Ther 2007, 26:889-898.
39. Rentz A.M., Kahrilas P., Stanghellini V., et al. Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders. Qual Life Res 2004, 13:1737-1749.
40. Rothman M., Farup C., Stewart W., et al. Symptoms associated with gastroesophageal reflux disease: development of a questionnaire for use in clinical trials. Dig Dis Sci 2001, 46:1540-1549.
41. Shikiar R., Flood E., Siddique R., et al. Development and validation of the Gastroesophageal Reflux Disease Treatment Satisfaction Questionnaire. Dig Dis Sci 2005, 50:2025-2033.
42. Revicki D.A., Rentz A.M., Tack J., et al. Responsiveness and interpretation of a symptom severity index specific to upper gastrointestinal disorders. Clin Gastroenterol Hepatol 2004, 2:769-777.
43. Miner P., Orr W., Filippone J., et al. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol 2002, 97:1332-1339.
44. Brzana R.J., Koch K.L. Gastroesophageal reflux disease presenting with intractable nausea. Ann Intern Med 1997, 126:704-707.
45. Farup C., Kleinman L., Sloan S., et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med 2001, 161:45-52.
46. Xu J.Y., Xie X.P., Song G.Q., et al. Healing of severe reflux esophagitis with PPI does not improve esophageal dysmotility. Dis Esophagus 2007, 20:346-352.
47. Parkman H.P., Urbain J.L., Knight L.C., et al. Effect of gastric acid suppressants on human gastric motility. Gut 1998, 42:243-250.
48. Tougas G., Earnest D.L., Chen Y., et al. Omeprazole delays gastric emptying in healthy volunteers: an effect prevented by Tegaserod. Aliment Pharmacol Ther 2005, 22:59-65.
49. Jones M.P., Shah D., Ebert C.C. Effects of rabeprazole sodium on gastric emptying, electrogastrography, and fullness. Dig Dis Sci 2003, 48:69-73.
50. Grudell A.B., Camilleri M., Burton D.D., et al. Effect of a proton pump inhibitor on postprandial gastric volume, emptying and symptoms in healthy human subjects: a pilot study. Aliment Pharmacol Ther 2006, 24:1037-1043.
51. Vidon N., Dutreuil C., Scoule J.C., et al. Does lansoprazole influence postprandial digestive function?. Aliment Pharmacol Ther 1993, 7:629-634.
52. Guillemot F., Ducrotté P., Bueno L. Prevalence of functional gastrointestinal disorders in a population of subjects consulting for gastroesophageal reflux disease in general practice. Gastroenterol Clin Biol 2005, 29:243-246.
53. De Vries D.R., Van Herwaarden M.A., Baron A., et al. Concomitant functional dyspepsia and irritable bowel syndrome decrease health-related quality of life in gastroesophageal reflux disease. Scand J Gastroenterol 2007, 42:951-956.
54. Yarandi S.S., Nasseri-Moghaddam S., Mostajabi P., et al. Overlapping gastroesophageal reflux disease and irritable bowel syndrome: increased dysfunctional symptoms. World J Gastroenterol 2010, 16:1232-1238.
55. Wiklund I.K., Junghard O., Grace E., et al. Quality of Life in Reflux and Dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg Suppl 1998, 41-49.
56. Shaw M., Dent J., Beebe T., et al. The Reflux Disease Questionnaire: A measure for assessment of treatment response in clinical trials. Health Qual Life Outcomes 2008, 6:31.
57. Talley N.J., Phillips S.F., Melton J., et al. A patient questionnaire to identify bowel disease. Ann Intern Med 1989, 111:671-674.
58. Jacobson B.C., Delemos B., Sun Y. Treatment outcomes with rabeprazole (RAB) 20 mg vs placebo (Pbo) in overweight/obese patients with nonerosive reflux disease (NERD): analysis of 2 US multicenter trials. Gastroenterology 2007, 132:A493.
59. Kahrilas PJ, Delemos B, Xiang J. Associated symptoms in nonerosive gastroesophageal reflux disease (NERD): effect of PPI therapy. 9th Meeting of the World Organization for Specialized Studies on Diseases of the Esophagus (OESO), Monte Carlo, Monaco, 2008.